Robert Califf (Pablo Martinez Monsivais, AP Images)

FDA com­mish nom­i­nee's fi­nan­cial dis­clo­sures re­veal a vast web of in­dus­try ties. Will they mat­ter?

Pres­i­dent Biden’s nom­i­nee to run the FDA was hit with some tepid crit­i­cism back in 2016 for be­ing too cozy with the bio­phar­ma in­dus­try be­cause some of the tri­als he ran had in­dus­try spon­sors and some of the fund­ing he took was from in­dus­try.

Nev­er­the­less, Rob Califf sailed through his con­fir­ma­tion then, and his suc­ces­sor Scott Got­tlieb showed that even clos­er ties to in­dus­try shouldn’t stop an ef­fec­tive leader from be­ing FDA com­mis­sion­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.